Chorley and South Ribble Clinical Commissioning Group and Greater Preston Clinical Commissioning Group (CCG)

Policies for the Commissioning of Healthcare

Pan-Lancashire policy for commissioning spinal injections and radiofrequency denervation for low back pain

<table>
<thead>
<tr>
<th></th>
<th>Introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>This document is part of a suite of policies that the CCG uses to drive its commissioning of healthcare. Each policy in that suite is a separate public document in its own right, but will be applied with reference to other policies in that suite.</td>
</tr>
</tbody>
</table>

| 1.2 | This policy is based on the CCGs’ Statement of Principles for Commissioning of Healthcare (version in force on the date on which this policy is adopted). |

<table>
<thead>
<tr>
<th>2</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Invasive, non-surgical interventions and treatments for low back pain and sciatica must be considered in line with NICE NG59.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.2</th>
<th>Spinal Injections- Non-specific low back pain (NSLBP)</th>
</tr>
</thead>
</table>

The CCG considers that, in line with NICE Guidance NG59, spinal injections for managing NSLBP do not accord with the Principle of Effectiveness, therefore the CCG will not routinely commission this intervention.

<table>
<thead>
<tr>
<th>2.3</th>
<th>Spinal Injections- Radicular pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3.1</td>
<td>An initial assessment should be undertaken in line with NICE guidance, NG59.</td>
</tr>
</tbody>
</table>

| 2.3.2 | The use of non-pharmacological & pharmacological interventions, including self-management, should be optimised prior to injection therapy. |

**Eligibility criteria:**

<table>
<thead>
<tr>
<th>2.3.3</th>
<th>The CCG will commission spinal facet joint and epidural injections for the management of radicular pain when the following criteria are satisfied:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3.3.1</td>
<td>The patient has <strong>acute and severe sciatica</strong> and</td>
</tr>
<tr>
<td>2.3.3.2</td>
<td>The injections are part of a multimodal, multidisciplinary management plan (injection + medications + physiotherapy +/- CBT)</td>
</tr>
</tbody>
</table>

<p>| 2.3.4 | Where there is an existing community service commissioned by the CCG, a maximum of two spinal injections will be funded prior to Consultant referral for further management, provided the eligibility criteria at section 2.3.3 are met. |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3.5</td>
<td>Following referral to a Consultant:</td>
</tr>
<tr>
<td>2.3.5.1</td>
<td>- Selective nerve root blocks or DRG block can be used for diagnostic purposes, provided the eligibility criteria at section 2.3.3 are met.</td>
</tr>
<tr>
<td>2.3.5.2</td>
<td>- A maximum of two therapeutic spinal injections will be funded within any individual treatment cycle prior to patient discharge or surgical referral, provided the eligibility criteria at section 2.3.3 are met.</td>
</tr>
<tr>
<td>2.4</td>
<td>Spinal Injections- Specific low back pain</td>
</tr>
<tr>
<td>2.4.1</td>
<td>An initial assessment should be undertaken in line with NICE guidance, NG59.</td>
</tr>
<tr>
<td>2.4.2</td>
<td>The use of non-pharmacological &amp; pharmacological interventions, including self-management, should be optimised prior to injection therapy.</td>
</tr>
<tr>
<td>2.4.3</td>
<td>Eligibility criteria:</td>
</tr>
<tr>
<td>2.4.3.1</td>
<td>The CCG will commission spinal injections for the management of specific low back pain when the following criteria is satisfied:</td>
</tr>
<tr>
<td>2.4.4</td>
<td>Where there is an existing community service commissioned by the CCG, a maximum of two spinal injections will be funded prior to Consultant referral for further management, provided the eligibility criteria above are met.</td>
</tr>
<tr>
<td>2.4.5</td>
<td>Following referral to a Consultant a maximum of two further therapeutic spinal injections will be funded within any individual treatment cycle prior to patient discharge or surgical referral.</td>
</tr>
<tr>
<td>2.5</td>
<td>Radiofrequency denervation</td>
</tr>
<tr>
<td>2.5.1</td>
<td>The CCG will commission radiofrequency denervation in the following circumstances:</td>
</tr>
<tr>
<td>2.5.1.1</td>
<td>- In people with chronic low back pain (rated as 5 or more on a visual analogue scale, or equivalent) following a positive response to a diagnostic medial branch block</td>
</tr>
<tr>
<td>2.5.1.2</td>
<td>- The CCG will commission repeat radiofrequency denervation after a period of 6 months, provided the discharge criteria set out in section 8.3.3 below are met.</td>
</tr>
<tr>
<td>2.5.2</td>
<td>The following patient discharge criteria must be adhered to by all clinicians following radiofrequency denervation treatment:</td>
</tr>
<tr>
<td>2.5.2.1</td>
<td>- Patients must be discharged from the service post denervation if pain relief is &gt;50% for a period of &gt;4 months.</td>
</tr>
<tr>
<td>2.5.2.2</td>
<td>- Should a new referral be required, this must be accompanied by</td>
</tr>
</tbody>
</table>
completion of a new assessment within primary care.

3 Scope and definitions

3.1 The scope of this policy includes the use of spinal injections and radiofrequency denervation for the management of low back pain in patients over the age of 16 years.

3.2 The scope of this policy does not include the specific management of back pain related to the following conditions:
- Infection
- Trauma (e.g. fractured spine which may need vertebroplasty or kyphoplasty as approved by NICE)
- Inflammatory disease such as spondyloarthritis
- The evaluation of people with sciatica with progressive neurological deficit or cauda equina
- Scoliosis
- Spinal injury
- Metastatic spinal cord compression
- Suspected cancer

If serious underlying pathology is suspected refer to the relevant NICE guidance.

3.3 The CCG recognises that a patient may have certain features, such as
- having back pain,
- wishing to have a service provided for back pain,
- being advised that they are clinically suitable for spinal injections, and
- being distressed by their back pain, and by the fact that they may not meet the criteria specified in this commissioning policy.

Such features place the patient within the group to whom this policy applies and do not make them exceptions to it.

3.4 There are three groupings of pathologies that commonly affect the lumbar spine and cause back pain for which injections have been considered. These groups however, are very different in their response to injection therapy. Before treatment, patients need adequate assessment within a multi-disciplinary team and management approach to make a diagnosis or diagnoses. Injections could be part of the diagnosis process (diagnostic block).

For the purpose of this policy the CCG defines the groups as follows:

**A) Radicular pain** - Patients with nerve root compression irritation and/or inflammation. Patients typically present with predominantly leg pain or sciatica.
The two most common causes of radicular pain are prolapsed (herniated) intervertebral disc and spinal canal stenosis. Patients should be managed on an explicit care pathway with explicit review and decision points.
Injection therapy for radicular pain in a carefully selected patient is an appropriate procedure and is therefore funded in certain circumstances. See section 2.3 for eligibility criteria.

**B) Non-specific low back pain (NSLBP)** – is low back pain not attributable to a specific pathology or cause. It is not associated with potentially serious causes (e.g. infection, tumour, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome). The management of non-specific low back pain represents a challenge in health care provision.

NSLBP is also known as low back pain, mechanical, musculoskeletal or simple low back pain (NG59)

Injection therapy is not an appropriate procedure for NSLBP, as advised by NICE NG59, and is therefore not funded.

**C) Specific low back pain** - is back pain attributed to a specific pathology or cause. Specific back pain can have multiple causes including: Myofascial pain, specific disc bulge, failed back surgery, fracture vertebra, inflammation/stress of sacroiliac or facet joints (after positive diagnostic block) or lumbar sympathetic nerves pathology.

Injection therapy for specific low back pain in carefully selected patients within a multi-disciplinary team management approach is an appropriate procedure and is therefore funded in certain circumstances. See section 2.4 for eligibility criteria.

### 3.5 Relevant evidence and guidelines have been reviewed including the recommendations of:

- NICE quality standard published 27 July 2017
  [https://nice.org.uk/guidance/qs155](https://nice.org.uk/guidance/qs155)
- NICE guidance published 30th November 2016
  [https://www.nice.org.uk/guidance/ng59](https://www.nice.org.uk/guidance/ng59)
- NHSE National Pathway of Care for Low Back Pain & Radicular Pain December 2014
- Royal College of Surgeons Commissioning Guide: Low back pain 2013 and NHSE Guide to Commissioners of Spinal Services January 2013
  [NHS RightCare](https://www.england.nhs.uk/rightcare/)

### 4 Appropriate Healthcare

#### 4.1 Spinal facet joint and epidural injections are invasive treatments that are used in two ways:

- **First (Diagnostic):** Selective nerve root block can be used to diagnose the source of radicular back pain. Medial branch block is recognised as a diagnostic tool to diagnose the source of facet joints pain.
- **Second (Therapeutic):** spinal facet joint injections and epidural
injections are used as a treatment to relieve both radicular and specific pain low back pain.

4.2 The CCG regards the achievement of this purpose as according with the Principle of Appropriateness. Therefore, this policy does not rely on the principle of appropriateness. Nevertheless, if a patient is considered exceptional in relation to the principles on which the policy does rely, the CCG may consider the principle of appropriateness in the particular circumstances of the patient in question before confirming a decision to provide funding.

5 Effective Healthcare

5.1 The following policy criteria rely on the principle of effectiveness:
- The criterion at section 2.2 relating to NSLBP; NICE NG59 states there was no consistent good quality evidence to recommend the use of spinal injections for the management of non-specific low back pain. There was minimal evidence of benefit from injections, and reason to believe that there was a risk of harm, even if rare.

6 Cost Effectiveness

6.1 The CCG does not call into question the cost-effectiveness of spinal facet joint and caudal injections and therefore this policy does not rely on the Principle of Cost-Effectiveness. Nevertheless, if a patient is considered exceptional in relation to the principles on which the policy does rely, the CCG may consider whether the treatment is likely to be cost-effective in this patient before confirming a decision to provide funding.

7 Ethics

7.1 The CCG does not call into question the ethics of spinal facet joint and caudal injections and therefore this policy does not rely on the Principle of Ethics. Nevertheless, if a patient is considered exceptional in relation to the principles on which the policy does rely, the CCG may consider whether the treatment is likely to raise ethical concerns in this patient before confirming a decision to provide funding.

8 Affordability

8.1 The CCG does not call into question the affordability of spinal facet joint and caudal injections and therefore this policy does not rely on the Principle of Affordability. Nevertheless, if a patient is considered exceptional in relation to the principles on which the policy does rely, the CCG may consider whether the treatment is likely to be affordable in this patient before confirming a decision to provide funding.

9 Exceptions

9.1 The CCG will consider exceptions to this policy in accordance with the Policy for Considering Applications for Exceptionality to Commissioning Policies.
9.2 In the event of inconsistency, this policy will take precedence over any non-
mandatory NICE guidance in driving decisions of this CCG. A circumstance
in which a patient satisfies NICE guidance but does not satisfy the criteria in
this policy does not amount to exceptionality.

10 Force

10.1 This policy remains in force until it is superseded by a revised policy or by
mandatory NICE guidance relating to this intervention, or to alternative
treatments for the same condition.

10.2 In the event of NICE guidance referenced in this policy being superseded by
new NICE guidance, then:
- If the new NICE guidance has mandatory status, then that NICE
guidance will supersede this policy with effect from the date on which it
becomes mandatory.
- If the new NICE guidance does not have mandatory status, then the
CCG will aspire to review and update this policy accordingly. However, until the CCG adopts a revised policy, this policy will remain
in force and any references in it to NICE guidance will remain valid as
far as the decisions of this CCG are concerned.

11 References

NHS England (2013) Guide to the Commissioners of Spinal Services
http://www.nationalspinaltaskforce.co.uk/pdfs/NHSSpinalReport_vis7%2030.01.13.pdf

Royal College of Surgeons Commissioning Guide: Low back pain 2013
http://www.rcseng.ac.uk/healthcare-bodies/docs/commissioning-guides-boa/lower-back-paincommissioning-guide

NHS Guidelines CG 88 (May 2009) Low Back Pain in Adults: Early Management
https://www.nice.org.uk/Guidance/CG88

http://www.rcseng.ac.uk/healthcare-bodies/docs/pathfinder-low-back-and-radicular-pain

NHS Wiltshire CCG “Managing Back Pain - Spinal Facet Joint and Epidural Injections Policy” (July 2014)

NHS Shropshire CCG “PROCEDURES OF LIMITED CLINICAL VALUE POLICY” (September 2015)
Appendix 1: Associated OPCS codes

The codes applicable to this policy are:

<table>
<thead>
<tr>
<th>OPCS codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A521, A522, A528, A529, A573, A574, A575, A577, V485, V486, V487, V488, V544, W903, X375, X382</td>
</tr>
</tbody>
</table>

Date of adoption: 01.11.2018
Date for review: 01.11.2021